BioMarin Pharmaceutical Inc. is marketing $2.85 billion in junk debt to help fund its acquisition of Amicus Therapeutics Inc., adding to a flurry of financing offerings.
The company, which on Friday launched the sale of a seven-year, $2 billion term loan, is also offering $850 million in eight-year high-yield notes, according to people with direct knowledge of the matter.
That is the latest acquisition-related financing to hit the market in a year that’s slated to be one of the strongest for such deals. Banks underwrote about $65 billion of financing tied to leveraged buyouts that they are expected ...
